AFP and hepatoblastoma: Hence, subjects with earlier hepatoblastoma onset (≤1.25 years) may have greater chemosensitivity, a greater likelihood of AFP levels <1200 ng/mL after neoadjuvant chemotherapy, and thus improved native liver and overall survivals as compared with those diagnosed after 1.25 years.